You are hereOctober 8, 2019
Engineered hiPSC-CMs for Action Potential Assessments
While genetically encoded fluorescent voltage indicators can report on action potentials in human induced pluripotent stem cell‐derived cardiomyocytes (hiPSC‐CMs), the transfection process presents several drawbacks. To solve this problem, researchers from the laboratory of Deborah K. Lieu (University of California, Davis, Sacramento, California, USA) report on an hiPSC line stably expressing “ArcLight” from the AAVS1 safe harbor locus generated by CRISPR/Cas9. Sun et al. report in STEM CELLS that ArcLight expression persists following myocardial differentiation, thereby allowing the repeated assessment of action potentials in hiPSC‐derived cardiomyocytes.
Furthermore, read the Stem Cells Portal Press Release for more information regarding this study!